Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits

Pate, David W.; Järvinen, Kristiina; Urtti, Arto; Mahadevan, V.; Järvinen, Tomi

doi:10.1016/s0024-3205(98)00499-8

Cited by 64 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CB 1 -receptor expression in the ciliary process and trabecular meshwork tissues, as demonstrated in bovine and human eyes (Stamer et al 2001), may be the mechanistic basis for these observations. Systemic administration of rimonabant alone increased IOP in rabbits (Pate et al 1998), a finding in line with the presence of anandamide in the human eye (Stamer et al 2001). Moreover, rimonabant was also reported to inhibit prostaglandin-induced contraction of human ciliary muscle (Romano and Lograno 2007).…”

Section: Other Peripheral Effectsmentioning

confidence: 57%

“…Based upon the clinical observation that smoking marijuana can decrease the intraocular pressure (IOP), several studies have been done on ocular function. In vivo studies with topical cannabinoid administration in rabbits have consistently demonstrated a lowering of IOP, an effect that has been abolished by either systemic (Laine et al 2002;Pate et al 1998) or local administration of rimonabant (Song and Slowey 2000). The synthetic cannabinoid WIN 55,212-2 administered as eye drops lowered intraocular pressure in humans suffering from glaucoma (Porcella et al 2001).…”

Section: Other Peripheral Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Diepen

Schlicker

Michel

2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Rimonabant is an inverse agonist specific for cannabinoid receptors and selective for their cannabinoid-1 (CB 1 ) subtype. Although CB 1 receptors are more abundant in the central nervous system, rimonabant has many effects in the periphery, most of which are related to prejunctional modulation of transmitter release from autonomic nerves. However, CB 1 receptors are also expressed in, e.g., adipocytes and endothelial cells. Rimonabant inhibits numerous cardiovascular cannabinoid effects, including the decrease of blood pressure by central and peripheral (cardiac and vascular) sites of action, with the latter often being endothelium dependent. Rimonabant may also antagonize cannabinoid effects in myocardial infarction and in hypotension associated with septic shock or liver cirrhosis. In the gastrointestinal tract, rimonabant counteracts the cannabinoid-induced inhibition of secretion and motility. Although not affecting most cannabinoid effects in the airways, rimonabant counteracts inhibition of smoothmuscle contraction by cannabinoids in urogenital tissues and may interfere with embryo attachment and outgrowth of blastocysts. It inhibits cannabinoid-induced decreases of intraocular pressure. Rimonabant can inhibit proliferation of, maturation of, and energy storage by adipocytes. Among the many cannabinoid effects on hormone secretion, only some are rimonabant sensitive. The effects of rimonabant on the immune system are not fully clear, and it may inhibit or stimulate proliferation in several types of cancer. We conclude that direct effects of rimonabant on adipocytes may contribute to its clinical role in treating obesity. Other peripheral effects, many of which occur prejunctionally, may also contribute to its overall clinical profile and lead to additional indications as well adverse events.

show abstract

Section: Other Peripheral Effectsmentioning

confidence: 57%

Section: Other Peripheral Effectsmentioning

confidence: 99%

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Diepen

Schlicker

Michel

2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…Pate et al (1998) administered AEA, its R-alpha-isopropyl analogue, and the non-classical cannabinoid CP-55,940 into the eyes of normotensive rabbits. These substances were dissolved in an aqueous 10-20% 2-hydroxypropyl-beta-cyclodextrin solution (containing 3% polyvinyl alcohol).…”

Section: The Use Of Cannabinoids In Animalsmentioning

confidence: 99%

“…The low solubility of the cannabinoids in water was modified with cyclodextrins. It was shown that CP-55,940 had considerable ocular hypotensive effects, R-alpha-isopropyl anandamide exerted these effects to a smaller extent and AEA caused a typical bi-phasic initial hypertension and subsequent decrease in intraocular pressure (Pate et al 1998). Song and Slowey (2000) administered the substance WIN 55212-2 (CB 1, 2 receptor agonist) topically into the eyes of healthy rabbits at doses of 4, 20 and 100 μg.…”

Section: The Use Of Cannabinoids In Animalsmentioning

confidence: 99%

The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review

Landa¹,

Šulcová²,

Gbelec³

2016

Vet. Med. - Czech

View full text Add to dashboard Cite

Cannabinoids/medical marijuana and their possible therapeutic use have received increased attention in human medicine during the last years. This increased attention is also an issue for veterinarians because particularly companion animal owners now show an increased interest in the use of these compounds in veterinary medicine. This review sets out to comprehensively summarise well known facts concerning properties of cannabinoids, their mechanisms of action, role of cannabinoid receptors and their classification. It outlines the main pharmacological effects of cannabinoids in laboratory rodents and it also discusses examples of possible beneficial use in other animal species (ferrets, cats, dogs, monkeys) that have been reported in the scientific literature. Finally, the article deals with the prospective use of cannabinoids in veterinary medicine. We have not intended to review the topic of cannabinoids in an exhaustive manner; rather, our aim was to provide both the scientific community and clinical veterinarians with a brief, concise and understandable overview of the use of cannabinoids in veterinary medicine.

show abstract

“…They found that WIN55212-2, a synthetic cannabinoid known to have strong affinity for the CB1 receptor, did not produce any IOP-lowering effects when given systemically to normotensive rabbits. A welldesigned experiment by Pace et al 21 swung the pendulum back in favour of the IOP reduction-CB1 receptor relationship when it was demonstrated that normotensive rabbits pretreated with a subcutaneous injection of a known CB1 receptor antagonist showed no IOP reduction following topical administration of two synthetic cannabinoids. The same two cannabinoids, meanwhile, when applied topically to rabbits not pretreated with the CB1 receptor antagonist, caused a significant IOP reduction.…”

Section: Department Of Human Biology 2 Faculty Of Medicine -Universimentioning

confidence: 99%

Evaluating Non-Conventional Treatments for Glaucoma: A Review Article

Zakrzewski¹,

Kus²

2008

HYP

View full text Add to dashboard Cite

Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits

Cited by 64 publications

References 13 publications

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review

Evaluating Non-Conventional Treatments for Glaucoma: A Review Article

Contact Info

Product

Resources

About